Patheon IncTSX: PTI

Patheon Inc. - Trading Investigation Closed

· Issued by Patheon Inc via CNW
Website: www.patheon.com

TORONTO, Dec. 22 /CNW/ - Patheon Inc. (TSX: PTI) today announced that its
external counsel has received a letter from Staff of the Ontario Securities
Commission ("OSC"), dated December 20, 2005, stating that after reviewing the
evidence in relation to certain trading in shares of Patheon Inc. by the Chief
Executive Officer and the President and Chief Operating Officer, OSC Staff has
decided to close its investigation into the matter.
As previously disclosed by Patheon in a news release on November 9, 2004,
Staff of the OSC had been investigating whether Patheon's two senior officers,
the CEO and the President and COO, had undisclosed material information about
the company when they executed an order in January 2003 to sell shares in
connection with the exercise of stock options.

Patheon (TSX:PTI; www.patheon.com) is a leading global provider of drug
development and manufacturing services to the international pharmaceutical
industry. Patheon operates a network of 14 facilities in the United States,
Canada and Europe, employing more than 5,900 people and serving a client base
of 180 pharmaceutical and biotechnology companies.

%SEDAR: 00001700E

Patheon Inc on 6ix

Earlier from Patheon

Later from Patheon

All Patheon news releases